

For a safe and effective treatment with INOmax® (nitric oxide 800ppm)



Information card for healthcare professionals

Typical risks associated with the use of INOmax

- Risk of rebound effect and precaution to take when discontinuing the treatment
- Risk of abrupt discontinuation of INOmax therapy in the event of critical failure of the delivery system and how to prevent it
- Risk of bleeding and haemostasis disorders
- Potential Risk if used in combination with other vasodilators which act on cGMP or cAMP

Risk mitigating measures to be taken

- Monitoring of Methaemoglobin level
- Monitoring of NO₂ formation

Please note that the list of risk and risk mitigating measures is not complete. Please read the product information carefully before using INOmax.

Linde: Living healthcare

Linde Medicale srl
Soluzioni e Servizi per la Sanità, Via Guido Rossa 3, 20004 Arluno (Mi)
Telefono +39.02.90373-1, Fax +39.02.90373-599
inamax.it@linde.com ; www.lindemedicale.it

Suspected Adverse Drug Reactions may be reported either to
Medicines Authority: postlicensing.medicinesauthority@gov.mt
Marketing Authorization Holder: vigilance@linde.com